摘要
Abstract
OBJECTIVE: To evaluate the effectiveness and economics of Danshen ligustrazine injection and Shenxiong glucose injection in the treatment of cerebral infarction, and to provide reference for clinical treatment decisions. METHODS: Retrieved from CNKI, VIP, WANFANG DATA and CBM, RCTs about Danshen ligustrazine injection or Shenxiong glucose injection vs. Compound danshen injection in the treatment of cerebral infarction were collected. Clinical efficacies of two drugs were compared indirectly by using Meta-analysis, and the costs were obtained through domestic routine treatment plan and cost level. Based on it, pharmacoeconomic cost-effectiveness analysis was conducted. RESULTS: A total of 14 literatures were included, involving 1 305 patients. Average total response rates of Danshen ligustrazine group and Shenxiong glucose injection group were 89. 63％ and94. 11％, and the costs were 3 855. 29 and 4 198. 68 yuan, respectively; cost-effectiveness ratio were 43. 01 and 44. 61. The incremental cost-effectiveness ratio was 76. 65, i. e. Shenqiong glucose injection group needed extra cost of 76. 65 yuan for each additional 1％ of the average total response rate, which was higher than the daily disposable income of 60. 18 yuan in China. Meanwhile, the results of cost-effectiveness analysis were supported by sensitivity analysis. CONCLUSIONS: Compared to Shenxiong glucose injection, Danshen ligustrazine injection is probably more cost-effective for cerebral infarction. Furthermore, the conclusion need to be confirmed by pharmacoeconomics evaluation based on RCTs.关键词
脑梗死/丹参川芎嗪注射液/参芎葡萄糖注射液/Meta分析/成本-效果分析Key words
Cerebral infarction/Danshen ligustrazine injection/Shenxiong glucose injection/Meta-analysis/Cost-effectiveness analysis分类
医药卫生
